DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study

Miura, Itaru; Kunii, Yasuto; Hino, Mizuki; Hoshino, Hiroshi; Matsumoto, Junya; Kanno-Nozaki, Keiko; Horikoshi, Sho; Kaneko, Haruka; Bundo, Miki; Iwamoto, Kazuya

doi:10.1016/j.jpsychires.2018.02.018

Cited by 17 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preliminary epigenetic findings suggest that methylation levels at CpG site 387 of ANKK1 may be associated with the treatment response to aripiprazole in patients with schizophrenia. Furthermore, methylation of ANKK1 may affect dopaminergic neural transmission in the treatment of schizophrenia, and may influence treatment response (Miura et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

CLASH-VLT: a full dynamical reconstruction of the mass profile of Abell S1063 from 1 kpc out to the virial radius

Sartoris

Biviano

Rosati

et al. 2020

A&A

View full text Add to dashboard Cite

Context. The shape of the mass density profiles of cosmological halos informs us of the nature of dark matter (DM) and DM-baryons interactions. Previous estimates of the inner slope of the mass density profiles of clusters of galaxies are in opposition to predictions derived from numerical simulations of cold dark matter (CDM). Aims. We determine the inner slope of the DM density profile of a massive cluster of galaxies, Abell S1063 (RXC J2248.7−4431) at z = 0.35, with a dynamical analysis based on an extensive spectroscopic campaign carried out with the VIMOS and MUSE spectrographs at the ESO VLT. This new data set provides an unprecedented sample of 1234 spectroscopic members, 104 of which are located in the cluster core (R ≲ 200 kpc), extracted from the MUSE integral field spectroscopy. The latter also allows the stellar velocity dispersion profile of the brightest cluster galaxy (BCG) to be measured out to 40 kpc. Methods. We used an upgraded version of the MAMPOSSt technique to perform a joint maximum likelihood fit to the velocity dispersion profile of the BCG and to the velocity distribution of cluster member galaxies over a radial range from 1 kpc to the virial radius (r200 ≈ 2.7 Mpc). Results. We find a value of γDM = 0.99 ± 0.04 for the inner logarithmic slope of the DM density profile after marginalizing over all the other parameters of the mass and velocity anisotropy models. Moreover, the newly determined dynamical mass profile is found to be in excellent agreement with the mass density profiles obtained from the independent X-ray hydrostatic analysis based on deep Chandra data, as well as the strong and weak lensing analyses. Conclusions. Our value of the inner logarithmic slope of the DM density profile γDM is in very good agreement with predictions from cosmological CDM simulations. We will extend our analysis to more clusters in future works. If confirmed on a larger cluster sample, our result makes this DM model more appealing than alternative models.

show abstract

Section: Introductionmentioning

confidence: 99%

CLASH-VLT: a full dynamical reconstruction of the mass profile of Abell S1063 from 1 kpc out to the virial radius

Sartoris

Biviano

Rosati

et al. 2020

A&A

View full text Add to dashboard Cite

show abstract

“…Our systematic review yielded 29 studies (Table 1). Eighteen studies analyzed methylation in patients with schizophrenia, four studies in patients with bipolar disorder, and seven studies in a combined sample of patients with schizophrenia and bipolar disorder. The majority (n=22) of studies included observational sampling, such as cross‐sectional or case‐control studies, and the remaining analyzed changes in a prospective manner.…”

Section: Resultsmentioning

confidence: 99%

“…The most commonly employed measurement utilized restriction enzymes (five studies) followed by transposable elements (two studies) and ELISA (one study). 26 Obs 133 SCZ AAP and TAP Blood Global Cheng et al 27 Obs and prosp 30 Obs 172 BD olanzapine and quetiapine Blood d EWAS and genespecific Kinoshita et al 31 Prosp 21 SCZ olanzapine Blood EWAS Li et al 32 Obs 92 SCZ; 99 BD; 92 HC AAP and TAP Blood global Lott et al 33 Obs 85 SCZ NR blood gene-specific Melas et al 34 Obs 177 SCZ; 171 HC AAP and TAP Blood Global and genespecific Mill et al 35 Obs 35 SZ; 35 BD; 35 HC NR Brain EWAS Miura et al 36 Prosp 34 SCZ risperidone Blood Gene-specific Moons et al 37 Obs 438 SCZ AAP and TAP Blood Gene-specific Nour El Huda et al 38 Obs 138 SCZ; 132 HC AAP and TAP Blood Gene-specific Rukova et al 39 Prosp 20 SCZ; 220 HC NR Blood EWAS Shi et al 40 Prosp 288 SCZ risperidone Blood Gene-specific Swathy et al 41 Obs 184 SCZ; 330 HC NR Blood Global Tang et al 42 Prosp 82 SCZ AAP and TAP Blood Gene-specific Venugopal et al 43 Prosp 47 SCZ; 47 HC AAP Blood Gene-specific Zong et al 44 Obs 279 SCZ; 265 HC AAP and TAP Blood Gene-specific Details of 29 studies included in the systematic review including study design, type of antipsychotic within study, sample type for DNA methylation analysis, and overall DNA methylation strategy. AAP = atypical antipsychotic; BD = bipolar disorder; HC = healthy control; MDD = major depressive disorder; NR = not reported; obs = observational; PR = primary relative; pros = prospective; scz = schizophrenia; TAP = typical antipsychotic; UPR = unaffected primary relative.…”

Section: Global Methylation Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

The pharmacoepigenetics of antipsychotic treatment in severe mental illness is a growing area of research that aims to understand the interface between antipsychotic treatment and genetic regulation. Pharmacoepigenetics may some day assist in identifying treatment response mechanisms or become one of the components in the implementation of precision medicine. To understand the current evidence regarding the effects of antipsychotics on DNA methylation a systematic review with qualitative synthesis was performed through Pubmed, Embase and Psychinfo from earliest data to June 2019. Studies were included if they analyzed DNA methylation in an antipsychotic‐treated population of patients with schizophrenia or bipolar disorder. Data extraction occurred via a standardized format and study quality was assessed. Twenty‐nine studies were identified for inclusion. Study design, antipsychotic type, sample source, and methods of DNA methylation measurement varied across all studies. Eighteen studies analyzed methylation in patients with schizophrenia, four studies in patients with bipolar disorder, and seven studies in a combined sample of schizophrenia and bipolar disorder. Twenty‐two studies used observational samples whereas the remainder used prospectively treated samples. Six studies assessed global methylation, five assessed epigenome‐wide, and 15 performed a candidate epigenetic study. Two studies analyzed both global and gene‐specific methylation, whereas one study performed a simultaneous epigenome‐wide and gene‐specific study. Only three genes were analyzed in more than one gene‐specific study and the findings were discordant. The state of the pharmacoepigenetic literature on antipsychotic use is still in its early stages and uniform reporting of methylation site information is needed. Future work should concentrate on using prospective sampling with appropriate control groups and begin to replicate many of the novel associations that have been reported.

show abstract

“…According to the reduction in PANSS total score after 2 months of olanzapine treatment, the SZ patients were divided into responders and non-responders. Those whose reduction in PANSS total score was ⩾30% were defined as responders, and those whose reduction in PANSS total score was <30% were defined as non-responders (Miura et al, 2018). The formula used to calculate the reduction rate of PANSS total score and the reduction rate of miR-195 expression was (Tb− a)/Ta×100%, where Tb is the total PANSS score or miR-195 expression level after treatment and Ta is the total PANSS score or miR-195 expression level at baseline.…”

Section: Methodsmentioning

confidence: 99%

MicroRNA-195 predicts olanzapine response in drug-free patients with schizophrenia: A prospective cohort study

Huang

Bao

et al. 2020

J Psychopharmacol

View full text Add to dashboard Cite

Background: Disturbances of microRNA-195 have been implicated in the pathogenesis of schizophrenia. However, microRNA-195 levels in schizophrenia are controversial. Aims: To the best of our knowledge, this is the first study to examine microRNA-195 levels in untreated schizophrenia patients and their relationship to olanzapine response. Methods: We recruited 81 untreated schizophrenia patients and 96 healthy controls. The patients received 2 months olanzapine treatment. MicroRNA-195 levels in peripheral blood mononuclear cells were measured using quantitative real-time polymerase chain reaction testing. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale. Results: No significant differences in microRNA-195 levels were found between patients and healthy controls ( p > 0.05). Olanzapine significantly reduced microRNA-195 levels after 2 months treatment ( p = 0.003). Interestingly, microRNA-195 levels decreased significantly in responders ( p = 0.010), but not in non-responders ( p > 0.05). Both baseline microRNA-195 levels ( p = 0.027, p = 0.030) and the reduction rate of microRNA-195 levels ( p = 0.034, p = 0.044) were positively associated with the reduction rate of Positive and Negative Syndrome Scale total score and general psychopathological subscale score. Multiple stepwise regression analysis revealed that baseline microRNA-195 level was an independent contributor to the reduction in Positive and Negative Syndrome Scale total score and the general psychopathological subscale score ( p = 0.018, p = 0.030). Finally, logistic regression analysis suggested that baseline microRNA-195 level can serve as a biomarker for response to olanzapine ( p = 0.037). Conclusions: Our data indicate that microRNA-195 level may predict symptomatic improvement and olanzapine response in schizophrenia patients, suggesting that microRNA-195 should be considered as a potential therapeutic target for antipsychotics.

show abstract

DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study

Cited by 17 publications

References 22 publications

CLASH-VLT: a full dynamical reconstruction of the mass profile of Abell S1063 from 1 kpc out to the virial radius

CLASH-VLT: a full dynamical reconstruction of the mass profile of Abell S1063 from 1 kpc out to the virial radius

Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review

MicroRNA-195 predicts olanzapine response in drug-free patients with schizophrenia: A prospective cohort study

Contact Info

Product

Resources

About